evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 9 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 5 · 55.6%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 2 · 22.2%Moderate 0 · 0%High 1 · 11.1%

Casirivimab/imdevimab vs placebo

Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

The review found no eligible studies for this question.

2 findings from 1 review

Casirivimab/imdevimab vs placebo

Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Casirivimab/imdevimab showed no clear difference in adverse events: all grades within 6 months compared with placebo (low certainty).

2 findings from 1 review

Casirivimab/imdevimab vs placebo

Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

It is very uncertain whether casirivimab/imdevimab changes adverse events: grade 3 to 4 within 6 months compared with placebo (very low certainty).

2 findings from 1 review